{"url_path":"/sec/inm/8-k/2026-07-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-080414-index.html","accession_number":"0001213900-26-080414","cik":"0001728328","ticker":"INM","issuer_name":"InMed Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-080414-index.html","primary_entity_key":"0001728328","primary_entity_name":"InMed Pharmaceuticals Inc."},"word_count":318,"has_tables":true,"body_markdown":"false\n0001728328\n\n0001728328\n\n2026-07-22\n2026-07-22\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934**\n\n** **\n\n**Date of Report (Date of earliest event reported):\nJuly 22, 2026**\n\n \n\n**INMED PHARMACEUTICALS INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**British Columbia, Canada**\n \n**001-39685**\n \n**98-1428279**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**Suite 1445 – 885 West Georgia St.**\n\n**Vancouver, British Columbia, Canada V6C 3E8**\n\n(Address of principal executive offices) (Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(604) 669-7207**\n\n** **\n\n**Not Applicable**\n\n(Former name or former address, if changed since\nlast report.)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☒\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n******Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Shares, no par value\n \nINM\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐"}